Literature DB >> 20929079

Age-related immunoglobulin G seroprevalence of human parvovirus B-19 in Israeli children.

Dan Miron1, Yoseph Horovitz, Anthony Luder, Frederic S Ohnona, Yechiel Schlesinger, Yechiel Schelisinger.   

Abstract

BACKGROUND: Human parvovirus B19 is a global and common infectious pathogen in humans, particularly in children.
OBJECTIVES: To assess the immunoglobulin G3 seroprevalence of B19 in children in Israel.
METHODS: Overall, 128 previously healthy children (1.5-17 years old) hospitalized for various diseases other than acute human parvovirus B19 infection were assessed for IgG to the virus by enzyme-linked immunosorbent assay.
RESULTS: The IgG seroprevalence increased from 22% in children aged 1.5-9 years to 52% in older children (P = 0.001).
CONCLUSIONS: Our data suggest that most acute parvovirus B19 infections in Israel occur in the early school years, and that by 18 years of age 50% of Israeli children have been infected by the virus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20929079

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  3 in total

Review 1.  Beyond Cytomegalovirus and Epstein-Barr Virus: a Review of Viruses Composing the Blood Virome of Solid Organ Transplant and Hematopoietic Stem Cell Transplant Recipients.

Authors:  Marie-Céline Zanella; Samuel Cordey; Laurent Kaiser
Journal:  Clin Microbiol Rev       Date:  2020-08-26       Impact factor: 26.132

2.  Seroepidemiology of parvovirus B19 among different age groups & pregnant women in India.

Authors:  Rajlakshmi Viswanathan; Babasaheb V Tandale; Manisha S Tamayachekar; Santoshkumar M Jadhav; Kirtee A Khutwad; Kiran R Munne
Journal:  Indian J Med Res       Date:  2017-07       Impact factor: 2.375

3.  Parvovirus B19V infection in Israel: prevalence and occurrence of acute infection between 2008 and 2013.

Authors:  O Mor; I Ofir; R Pavel; R Bassal; Z Kra-Oz; D Cohen; T Shohat; E Mendelson
Journal:  Epidemiol Infect       Date:  2015-05-20       Impact factor: 4.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.